SAB Biotherapeutics SABS
NASDAQ SABS
$3.11 +0.04 (+1.30%)
At close: Nov 11, 2026 · 4:00 PM EST

SAB Biotherapeutics (SABS) Net Long-Term Debt Issued (Repaid) (2020 - 2026)

Updated

SAB Biotherapeutics' Non-Current Debt came in at $541,644 for Q4 2022.

Analysis

SAB Biotherapeutics (SABS) Net Long-Term Debt Issued (Repaid) (2020 - 2026) Analysis & Trends

  • Going back by year, Non-Current Debt was $172,037 in FY2020.
  • The Q4 2022 figure represents the lowest quarterly Non-Current Debt since Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net LT Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.98 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 SAB Biotherapeutics 279.79 Mn -130.87 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -37,388.00
Dec 31, 2025 -36,675.00
Sep 30, 2025 -35,980.00
Jun 30, 2025 -311,139.00
Mar 31, 2025 -34,618.00
Dec 31, 2024 -274,091.00
Sep 30, 2024 -649,130.00
Jun 30, 2024 -252,327.00
Mar 31, 2024 -247,437.00
Dec 31, 2023 -287,433.00
Sep 30, 2023 -142,738.00
Jun 30, 2023 -363,788.00
Mar 31, 2023 -361,680.00
Dec 31, 2022 -3.79 Mn
Sep 30, 2022 -287,082.00
Jun 30, 2022 -800,183.00
Mar 31, 2022 -804,534.00
Dec 31, 2021 -2.53 Mn
Sep 30, 2021 -51,229.00
Jun 30, 2021 4.02 Mn
API Access

SAB Biotherapeutics Net Long-Term Debt Issued (Repaid) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=SABS&period=max&api_key=YOUR_API_KEY